Beta Bionics, Inc. (BBNX) Earnings
Beta Bionics, Inc. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $-0.62. BBNX has beaten EPS estimates in 4 of its last 5 reported quarters (average surprise +21.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 21, 2026 | $-0.53 | $-0.49 | +7.5% | $28M | +2.5% |
| Feb 17, 2026 | $-0.42 | $-0.30 | +28.6% | $32M | +18.5% |
| Oct 28, 2025 | $-0.45 | $-0.33 | +26.7% | $27M | -5.7% |
| Jul 29, 2025 | $-0.51 | $-0.39 | +23.5% | $23M | +6.1% |
| Mar 25, 2025 | $-0.42 | $-1.82 | -333.3% | $20M | +26.6% |
| Dec 31, 2023 | — | $-3.13 | — | $8M | — |
| Sep 30, 2023 | — | $-1.71 | — | $3M | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 21, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Q1 performance exceeded expectations with revenue driven by new patient starts and recurring revenue from pharmacy install base. - Gross margin was strong due to pharmacy install base and lower material costs. - Operating expenses increased, with sales and marketing driven by expanding field sales team, R&D by mint and bi-hormonal projects, and G&A by scaling. - Remediation efforts ongoing for FDA warning letter, including work on complaint handling. - Pipeline updates: Mint patch pump advanced toward 2027 launch, bi-hormonal system initiated phase 2A feasibility trial, Bionic Insights launched in healthcare provider portal, and continued interest in type 2 diabetes indication.
Guidance
- Revised full year 2026 revenue guidance raised to $131 - $136 million from prior $130 - $135 million. - Pharmacy mix guidance raised to 37 - 39% of new patient starts reimbursed through pharmacy from prior 36 - 38%. - Gross margin outlook raised to 57.5% - 59.5% from prior 55.5% - 57.5%. - Operating expenses expected to accelerate growth for remainder of the year due to sales force expansion, marketing investment, and spending on mint and bi-hormonal programs.
Segment performance
In Q1, the company delivered $27.6 million in net sales, growing 57% year over year. Revenue growth was driven by new patient starts and the growing pharmacy install base. Q1 gross margin was 59.5%, expanding 864 basis points year over year. The pharmacy install base generated high margin recurring revenue and crossed a threshold where it became accretive to gross margin. Lower cost of materials for the islet and one-time gross margin tailwinds also contributed. New patient starts declined more than 10% but less than 20% compared to Q4 2025, with a high 30s percentage of new patient starts accessing islet through the pharmacy channel, an increase from prior quarters. Approximately 70% of new patient starts came from people with diabetes using multiple daily injections prior to starting the islet.
Risks & headwinds
- Ongoing need to fully address FDA warning letter concerns, including work in other areas besides complaint handling. - Unpredictability in gross margin due to possible discrete and semi-unpredictable one-time charges in cost of sales. - Potential challenges in managing customer acquisition costs as the market becomes more competitive.
Analyst Q&A
Q: Mike Crackey asked about pharmacy channel new start percentage and Salesforce expansion.
A: Pharmacy channel new start percentage has a B2B sales, long cycle, and guidance acknowledges that. Salesforce expansion has more to happen with most expansion in first half of the year.
Q: David Roman asked about ADA guideline changes, GLP-1s, and OPEX.
A: ADA guideline changes not significantly impacting prescribing patterns. GLP-1s have limited impact on type 1 and insulin-managed type 2. OPEX will grow due to sales force expansion and direct-to-consumer advertising, with customer acquisition costs expected to decrease through building install base and brand.
Q: Frank Takanan asked about gross margin and cash burn.
A: Q1 had one-time gross margin tailwinds, and cash burn in Q1 was higher due to cash bonuses and working capital differences.
Q: John Block asked about sales revenue cadence and gross margin.
A: Not giving quarterly revenue guidance but first half of 2026 expected to have more revenue. Gross margin expected to uptick quarter over quarter from normalized Q1 number.
Q: Richard Newitter asked about pharmacy channel competition and economics.
A: More competitors in pharmacy channel make it more normal, and insulin pumps are non-commoditized limiting downward price pressure.
Q: Jeff Johnson asked about pharmacy rebates and mint timing.
A: Rebates balanced with copay assistance, and mint on track with timeline for 2027 launch.
Q: Jeffrey Cohen asked about cost of materials and bi-hormonal trials.
A: Lower cost of materials due to scale, and bi-hormonal trials updates not to be published.
Q: Matthew Blackman asked about new patient ads and Salesforce expansion.
A: Not commenting on new patient ads quantification, and Salesforce expansion involves both white space filling and replacing in covered areas.
Q: Travis Steed asked about revenue guidance and new patient starts.
A: Revenue guidance can be exceeded by islet confidence, clinical results, and new store sales. Q1 is weakest seasonally with uptick expected in subsequent quarters.
Q: Ryan Schiller asked about competition.
A: No recent impactful changes in competitive environment, focusing on getting word out about differentiated islet system